Handelsavisen
prelaunch
Companies Healthcare 4596.T
45
4596.T Tokyo Stock Exchange Pharmaceuticals

4596.T

¥56,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
7,8B JPY
P/E
EV / Rev
Div yield
0,00 %
Op margin
-3 173,1 %
ROE
-37,3 %
Net margin
-3 169,7 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of prescription drugs and related healthcare products.

Business. The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-37,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4596.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4596.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to ¥1,918,615,000, which significantly exceeds its total liabilities of ¥165,625,000, resulting in a current ratio of 12.51. This indicates a robust ability to meet short-term obligations. The price-to-book ratio of 4.81 suggests that the market values the company at a premium relative to its book value, which may reflect expectations of future earnings or intangible assets.

    Profitability metrics are currently negative, with a return on equity of -0.3728 and a return on assets of -0.3416, indicating that the company is not generating returns for shareholders or effectively utilizing its assets. The operating income and net income are both negative, with operating income at -¥676,983,000 and net income at -¥676,253,000, which is a significant concern for investors. These figures suggest that the company is experiencing operational challenges and may be incurring substantial costs that outweigh its revenues.

    The company's revenue is concentrated in a single business segment, as no specific segments are disclosed in the available data. Geographically, the company's exposure is not detailed, but the lack of segment information implies that it may not have a diversified geographic or product portfolio. This concentration could pose a risk if the company's primary market or product line experiences a downturn.

    The company's growth trajectory is currently negative, with a significant decline in operating and net income. The outlook for the current fiscal year is not provided, but the negative financial performance suggests a challenging period ahead. The company's capital expenditures are relatively low at -¥10,631,000, which may indicate a focus on cost control rather than expansion. However, the lack of investment in growth initiatives could hinder long-term competitiveness.

    Risk factors include the company's negative profitability and the potential for further financial distress. The risk assessment indicates low liquidity and dilution risks, but the negative operating cash flow of -¥583,000,000 is a red flag. The company has not issued any recent dilutive events, and the dilution potential is low, which is a positive aspect. However, the negative financial performance may necessitate future financing, which could lead to dilution if not managed carefully.

    Recent events, as reflected in the financial data, show a decline in earnings, with the last actual EPS at -¥10.59 and revenue at ¥21,340,000. These figures indicate a challenging period for the company, with no immediate signs of improvement. The company's financial health is a concern, and investors should monitor future filings and earnings reports for any signs of recovery or further deterioration.

    Key takeaways
    • The company has a strong liquidity position, with a current ratio of 12.51 and significant cash reserves.
    • Profitability is negative, with a return on equity of -0.3728 and a return on assets of -0.3416.
    • The company's revenue is concentrated in a single segment, and geographic exposure is not detailed.
    • Growth is currently negative, with a significant decline in operating and net income.
    • The company has low liquidity and dilution risks, but the negative operating cash flow is a concern.
    • Recent financial performance indicates a challenging period for the company, with no immediate signs of improvement.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥56,00
    Market cap
    ¥8.73B
    Enterprise value
    ¥6.83B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    4.8x
    P / Tangible book
    4.8x
    Tangible book
    ¥1.81B
    Net cash
    ¥1.90B
    Current ratio
    12.5
    Debt / equity
    0.0
    ROA
    -34.2%
    ROE
    -37.3%
    Cash conversion
    86.0%
    CapEx / revenue
    -49.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-3 173,1 %Bottom quartile
    Net Margin-3 169,7 %Bottom quartile
    ROE-37,3 %Bottom quartile
    Capex / Rev-49,8 %Bottom quartile
    D/E0,01Above median
    Cash Conv0,86Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 4596.T Market data — financials · 2026-05-26
    • Kubota Pharmaceutical Holdings Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4596.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage